Drug development programs and

Major customers for CRO services are the large global pharma (ceutical) companies. Half a dozen big pharma s (Pfizer, Glaxo SmithKline, Sanofi-Aventis, AstraZeneca, Johnson Johnson, and Merck) alone absorb an estimated 30% of all CRO spending. As for CMOs and also for CROs, biotech startup companies with their dichotomy between ambitious drug development programs and limited resources are the second most promising prospects after big pharma (see Section 12.3). 

At each stage of the drug development program and for each trial within that stage, sponsors need to be aware of the implications of their choice of a and their choice of p and the acceptability of these implications. The implications of each choice and the acceptability of these implications may change throughout the course of a clinical development program. 

Different administrations have different views on their accessibility to eventual applicants for product approvals. These attitudes vary over the years, but currently the UK and French authorities are regarded as open to discussion on drug development programs, and both encourage early inter-... 

Lead structure According to Valler and Green s definition a lead structure is a representative of a compound series with sufficient potential (as measured by potency, selectivity, pharmacokinetics, physicochemical properties, absence of toxicity and novelty) to progress to a full drug development program [12]. 

T. R. Sweeney, M Survey of Compoundsfrom the Hntiradiation Drug Development Program of the U.S. Army Medical Research and Development Command Walter Reed Army Institute of Research, Washington, D.C., 1979. 

In this chapter we describe the current insights into the evolution of viruses under pressure of antiviral therapy and the potential impact on viral fimess. As most recent work in this field has been done in the field of human immunodeficiency virus (HIV), we use the evolution of this virus as the basis for the chapter. Subsequently, we describe resistance evolution for Hepatitis B virus (HBV), where large progress has been made in recent years. Furthermore, we describe the resistance development for Hepatitis C virus (HCV), for which a very active drug development program is undertaken by several pharmaceutical companies. Finally, we discuss resistance evolution for Influenza. 

As the twentieth century came to a close, the job market for computational chemists had recovered from the 1992-1994 debacle. In fact, demand for computational chemists leaped to new highs each year in the second half of the 1990s [135]. Most of the new jobs were in industry, and most of these industrial jobs were at pharmaceutical or biopharmaceutical companies. As we noted at the beginning of this chapter, in 1960 there were essentially no computational chemists in industry. But 40 years later, perhaps well over half of all computational chemists were working in pharmaceutical laboratories. The outlook for computational chemistry is therefore very much linked to the health of the pharmaceutical industry itself. Forces that adversely affect pharmaceutical companies will have a negative effect on the scientists who work there as well as at auxiliary companies such as software vendors that develop programs and databases for use in drug discovery and development. 

We have developed the efficient synthesis of the SERM drug candidate 1 and successfully demonstrated the process on a multiple kilogram scale to support the drug development program. A novel sulfoxide-directed borane reduction of vinyl sulfoxides was discovered. The mechanistic details of this novel reaction were explored and a plausible mechanism proposed. The sequence of asymmetric oxidation of vinyl sulfoxides followed by stereospecific borane reduction to make chiral dihydro-1,4-benzoxathiins was applied to the asymmetric synthesis of a number of other dihydro-1,4-benzoxathiins including the sweetening agent 67. 

---